---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066355"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:42:28.952240+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway

## Summary
- Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.
- Cash, equivalents, and marketable securities $204.1M; cash runway expected through end of 2026.
- Phase 3 LUCIDITY trial of avexitide in PBH dosed first patient; enrollment complete 2025, topline data H1 2026.
- Phase 1 LUMINA trial of AMX0114 (ASO for ALS) dosed first patient; early cohort data expected in 2025.
- Closed $65.5M public offering of 19.7M shares in Jan 2025; Phase 2b ORION (PSP) data expected Q3 2025.

## SEC filing metadata
- accession: 0000950170-25-066355
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/0000950170-25-066355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/amlx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066355
- JSON: https://secwatch.observer/filing/0000950170-25-066355.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.